200 related articles for article (PubMed ID: 28300854)
1. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
[TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
[TBL] [Abstract][Full Text] [Related]
3. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
5. The use of oxybutynin for treating axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Neves S; Munia MA; BiscegliJatene F; Puech-Leão P
Ann Vasc Surg; 2011 Nov; 25(8):1057-62. PubMed ID: 22023940
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
7. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder.
Dmochowski RR; Staskin DR; Duchin K; Paborji M; Tremblay TM
Int J Clin Pract; 2014 Aug; 68(8):986-94. PubMed ID: 24666884
[TBL] [Abstract][Full Text] [Related]
8. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Artzi O; Loizides C; Zur E; Sprecher E
Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
[TBL] [Abstract][Full Text] [Related]
9. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Try C; Messikh R; Elkhyat A; Aubin F; Humbert RP
Rev Med Liege; 2012 Oct; 67(10):520-6. PubMed ID: 23167161
[TBL] [Abstract][Full Text] [Related]
10. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
11. Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.
Teivelis MP; Wolosker N; Krutman M; Kauffman P; Campos JR; Puech-Leão P
Clinics (Sao Paulo); 2014 Sep; 69(9):608-14. PubMed ID: 25318092
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
Wolosker N; Kauffman P; de Campos JRM; Faustino CB; da Silva MFA; Teivelis MP; Puech-Leão P
Int J Dermatol; 2020 Jun; 59(6):709-715. PubMed ID: 32301117
[TBL] [Abstract][Full Text] [Related]
13. Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers.
Del Boz J; Millán-Cayetano JF; Blázquez-Sánchez N; de Troya M
Pediatr Dermatol; 2016 May; 33(3):327-31. PubMed ID: 27122197
[TBL] [Abstract][Full Text] [Related]
14. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Wagg A; Dale M; Tretter R; Stow B; Compion G
Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
[TBL] [Abstract][Full Text] [Related]
15. Initial study of transdermal oxybutynin for treating hyperhidrosis.
Millán-Cayetano JF; Del Boz J; Toledo-Pastrana T; Nieto-Guindo M; García-Montero P; de Troya-Martín M
J Dermatol; 2017 Jun; 44(6):717-720. PubMed ID: 28106275
[TBL] [Abstract][Full Text] [Related]
16. Use of oxybutynin for treating plantar hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Yazbek G; Neves S; Puech-Leao P
Int J Dermatol; 2013 May; 52(5):620-3. PubMed ID: 23590378
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.
Wolosker N; Teivelis MP; Krutman M; de Paula RP; Kauffman P; de Campos JR; Puech-Leão P
Ann Vasc Surg; 2014 Jul; 28(5):1106-12. PubMed ID: 24512855
[TBL] [Abstract][Full Text] [Related]
18. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder.
Ko KJ; Kim KH; Kim SW; Kim SO; Seo JT; Choo MS; Lee JZ; Oh SJ; Kim HG; Min KS; Kim JH; Lee KS
J Urol; 2019 Sep; 202(3):564-573. PubMed ID: 31009289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
